Brian B Haines, Agnieszka Denslow, Peter Grzesik, Jennifer S Lee, Terry Farkaly, Jacqueline Hewett, Daniel Wambua, Lingxin Kong, Prajna Behera, Judith Jacques, Caitlin Goshert, Michael Ball, Allison Colthart, Mitchel H Finer, Melissa W Hayes, Sonia Feau, Edward M Kennedy, Lorena Lerner, Christophe Quéva
ONCR-177 is an engineered recombinant oncolytic herpes simplex virus (oHSV) with complementary safety mechanisms, including tissue-specific microRNA (miR) attenuation and mutant UL37 to inhibit replication, neuropathic activity, and latency in normal cells. ONCR-177 is armed with five transgenes for IL12, FLT3LG (extracellular domain [ECD]), CCL4, and antagonists to immune checkpoints PD-1 and CTLA-4. In vitro assays demonstrated that targeted miRs could efficiently suppress ONCR-177 replication and transgene expression, as could the HSV-1 standard-of-care therapy acyclovir...
December 22, 2020: Cancer Immunology Research